MENU
Showcases Stock ranks Forex

Ginkgo Bioworks Hldgs Inc (DNA)
1.01  -0.04 (-3.81%) 04-12 16:00
Open: 1.06 Pre. Close: 1.05
High: 1.07 Low: 1.01
Volume: 13,991,434 Market Cap: 2,174(M)
Stock Technical Analysis
Overall:     
Target: Six months: 1.37
One year: 1.50
Support: Support1: 0.99
Support2: 0.83
Resistance: Resistance1: 1.17
Resistance2: 1.28
Pivot: 1.09
Moving Averages: MA(5): 1.09
MA(20): 1.10
MA(100): 1.34
MA(250): 1.57
MACD: MACD(12,26): -0.04
Signal(12,26,9): -0.05
%K %D: %K(14,3): 29.62
%D(3): 46.93
RSI: RSI(14): 38.87
52-Week: High: 2.545
Low: 0.993
Change(%): -22.3
Average Vol(K): 3-Month: 21995
10-Days: 20784
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 1.072 - 1.079 1.079 - 1.084
Low: 0.995 - 1.003 1.003 - 1.01
Close: 0.999 - 1.011 1.011 - 1.02
Price, MAs and Bollinger Bands
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.

[ DNA ] has closed below the lower bollinger band by 1.1%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ DNA ] is to continue within current trading range. It is unclear right now based on current values. 61.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
Company profile
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Stock chart
Stock News
Sun, 14 Apr 2024
Recent uptick might appease Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) institutional owners after losing 61% over ... - Yahoo Lifestyle UK

Thu, 11 Apr 2024
What's Going On With Ginkgo Bioworks Stock? - Ginkgo Bioworks Holdings (NYSE:DNA) - Benzinga

Thu, 11 Apr 2024
Ginkgo Bioworks (NYSE:DNA) Hits New 52-Week Low at $1.03 - MarketBeat

Thu, 11 Apr 2024
Ginkgo Bioworks acquires AgBiome's platform assets (NYSE:DNA) - Seeking Alpha

Thu, 11 Apr 2024
Ginkgo Bioworks Announces Acquisition of AgBiome's Platform Assets - PR Newswire

Wed, 10 Apr 2024
Ginkgo Bioworks, Novo Nordisk expand R&D tie-up (NYSE:DNA) - Seeking Alpha

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Neutral
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 1650.00
Shares Float (M) 1120.00
% Held by Insiders 6.74
% Held by Institutions 83.72
Shares Short (K) 262240
Shares Short Prior Month (K) 250230
Stock Financials
EPS -0.460
Book Value (p.s.) 0.550
Profit Margin
Operating Margin -515.53
Return on Assets (ttm) -21.8
Return on Equity (ttm) -63.0
Qtrly Rev. Growth -64.6
Gross Profit (p.s.)
Sales Per Share 0.152
EBITDA (p.s.) -0.401
Qtrly Earnings Growth
Operating Cash Flow (M) -295.50
Levered Free Cash Flow (M) -116.14
Stock Valuation
PE Ratio -2.20
PEG Ratio -0.17
Price to Book value 1.84
Price to Sales 6.63
Price to Cash Flow -5.64
Stock Dividends
Dividend
Dividend Yield
Dividend Growth

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android